Extracellular Heat Shock Protein (Hsp)70 and Hsp90α Assist in Matrix Metalloproteinase-2 Activation and Breast Cancer Cell Migration and Invasion by Sims, Jessica D. et al.
Extracellular Heat Shock Protein (Hsp)70 and Hsp90a
Assist in Matrix Metalloproteinase-2 Activation and
Breast Cancer Cell Migration and Invasion
Jessica D. Sims
1, Jessica McCready
2, Daniel G. Jay
1*
1Department of Cellular and Molecular Physiology, Sackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, United States of
America, 2Department of Anatomy and Cellular Biology, Sackler School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, United States
of America
Abstract
Breast cancer is second only to lung cancer in cancer-related deaths in women, and the majority of these deaths are caused
by metastases. Obtaining a better understanding of migration and invasion, two early steps in metastasis, is critical for the
development of treatments that inhibit breast cancer metastasis. In a functional proteomic screen for proteins required for
invasion, extracellular heat shock protein 90 alpha (Hsp90a) was identified and shown to activate matrix metalloproteinase
2 (MMP-2). The mechanism of MMP-2 activation by Hsp90a is unknown. Intracellular Hsp90a commonly functions with a
complex of co-chaperones, leading to our hypothesis that Hsp90a functions similarly outside of the cell. In this study, we
show that a complex of co-chaperones outside of breast cancer cells assists Hsp90a mediated activation of MMP-2. We
demonstrate that the co-chaperones Hsp70, Hop, Hsp40, and p23 are present outside of breast cancer cells and co-
immunoprecipitate with Hsp90a in vitro and in breast cancer conditioned media. These co-chaperones also increase the
association of Hsp90a and MMP-2 in vitro. This co-chaperone complex enhances Hsp90a-mediated activation of MMP-2 in
vitro, while inhibition of Hsp70 in conditioned media reduces this activation and decreases cancer cell migration and
invasion. Together, these findings support a model in which MMP-2 activation by an extracellular co-chaperone complex
mediated by Hsp90a increases breast cancer cell migration and invasion. Our studies provide insight into a novel pathway
for MMP-2 activation and suggest Hsp70 as an additional extracellular target for anti-metastatic drug development.
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Introduction
Breast cancer is the most commonly diagnosed cancer among
women and is second only to lung cancer in cancer-related deaths
[1]. There are a variety of treatments for primary breast tumors
ranging from chemotherapies to tumor resection, but once breast
cancer has metastasized, there is a poor rate of patient survival [2].
There are currently no therapies that limit metastasis. Obtaining a
better understanding of the factors and mechanisms that regulate
breast cancer cell migration and invasion is crucial to the
development of treatments that limit breast cancer metastasis.
Extracellular proteins are thought to play an important role in
regulating cancer cell migration and invasion, [3,4] and due to
their accessibility, provide good targets for drug development. To
explore this role, our lab conducted a functional proteomic screen
for extracellular proteins that are essential for invasion in
fibrosarcoma cells. One protein that was identified in the screen
was extracellular heat shock protein 90a (Hsp90a).
Hsp90a is a highly conserved and abundant protein, constitut-
ing about 1% of the total intracellular protein [5,6]. In the
cytoplasm, Hsp90a has over 200 interacting proteins (hereafter
referred to as ‘‘client proteins’’) [7] and it commonly functions in
concert with various co-chaperones including Hsp70, Hsp40,
Hop, Hip, and p23. These proteins form a complex that binds to
client proteins and assists in their folding or activation. Briefly,
Hsp70 and Hsp40 form a complex with the client protein. This
complex binds to Hsp90a using Hop as a scaffold. ATP binds to
Hsp90a, initiating a conformation change that enables p23 to bind
to Hsp90a and causes Hsp70, Hsp40, and Hop to disassociate
from the complex. This facilitates the folding and activation of the
client protein, which is then released from the complex [5,8].
Many studies have focused on the intracellular role of Hsp90a
in tumorigenesis, [9,10,11] but recently its extracellular role in
migration and invasion is beginning to be elucidated. Hsp90a is
exported from cancer cells via exosomes and contributes to breast
cancer cell migration [12]. We, and others, have demonstrated
that extracellular Hsp90a enhances breast cancer cell invasiveness
through MMP-2 activation [13] as well as other client proteins
including ErbB2 and plasmin [7,12]. The mechanism of how
Hsp90a acts in the activation of these client proteins is not known.
We focus here on MMP-2 due to its well established role in
invasion and migration [14,15].
MMP-2 is a zinc-dependent endopeptidase and a member of
the metalloproteinase family, which degrades various components
of the extracellular matrix [16,17]. MMP-2 has been shown to be
important in development and cell motility, and has a well-
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from the cell as an inactive zymogen and, once outside, it is
activated through cleavage of its pro-domain [14]. MMP-2 is
thought to be primarily activated by the membrane type 1 matrix
metalloproteinase (MT1-MMP) and tissue inhibitors of metallo-
proteinases (TIMPs), but has also been shown to be activated in
the absence of MT1-MMP, suggesting the presence of alternative
modes of activation such as auto-activation [18].
Based on its intracellular function, we hypothesized that
extracellular Hsp90a enhances breast cancer migration and
invasion by activating MMP-2 with the assistance of the co-
chaperones, Hsp70, Hop, Hsp40, and p23. In this paper, we
demonstrate that these co-chaperones are secreted from breast
cancer cells and that they physically interact with Hsp90a, both as
recombinant proteins and in breast cancer cell conditioned media.
Additionally, the presence of these co-chaperones increases the
interaction of Hsp90a and MMP-2 in vitro. We show that Hsp90a,
Hsp70, Hsp40, Hop, and p23 by themselves do not cleave and
activate pro-MMP-2, but enhance auto-activation. This set of co-
chaperones is similar to the minimal complex needed for the
activation of intracellular proteins such as the steroid hormone
receptor [19]. We also provide evidence that Hsp70, as part of the
above complex, is important in the activation of MMP-2 in cancer
cell conditioned media. The inhibition of extracellular Hsp70
reduces MMP-2 activation and decreases cancer cell migration
and invasion, implicating this co-chaperone as an additional
extracellular therapeutic target.
Materials and Methods
Antibodies and Reagents
All antibodies were purchased from Assay Designs (MI), except
for anti-MMP-2, which was purchased from R&D (MN), and anti-
fibronectin which was purchased from BD (NJ). All recombinant
proteins were purchased from Assay Designs except for pro-MMP-
2, which was purchased from EMD (NJ). Batimastat was
purchased from Tocris Biosciences (MO) and 17-AAG was
purchased from R&D (MN). Unless noted, all other reagents
were purchased from Sigma (MO).
Cell Culture
MDA-MB-231 and HT-1080 cells were obtained from ATCC
and MDA-MB-231-s4175 cells were a kind gift from Dr. Joan
Massague ´. Cells were maintained in DMEM supplemented with
10% FBS, 1% non-essential amino acids, and 1% penicillin-
streptomycin. SUM1315 cells were a kind gift from Dr. Charlotte
Kuperwasser and were maintained in Hams F12 media supple-
mented with 5% FBS, 5 mg/mL insulin, 10 ng/ml epidermal
growth factor (EGF) and 1% penicillin-streptomycin. All cells were
grown at 37uC under 7.5% CO2.
Preparation of Cell Lysates and Conditioned Media
To prepare lysates, cells were lysed in 750 ml lysis buffer (20 mM
Tris pH 7.5, 1% Triton X-100, 3 ml/ml protease inhibitor cocktail
(Sigma)), incubated for 30 minutes on ice and spun down at
4000 RPM (3300 g) on a table top centrifuge for 4 minutes. The
supernatant was then collected and a Bicinchoninic Acid (BCA)
protein assay was performed (Pierce, IL). To prepare conditioned
media, 3 million cells were plated in a T-150 flask. Twenty-four
hours after plating, cells were washed twice with HBSS (Gibco) and
re-fed with 15 mL serum free DMEM with 1% non-essential amino
acids. The conditioned media were collected 48 hours later and
concentrated by centrifugation in centrifugal filters (Millipore, MA).
Protein quantification was determined by BCA assay.
Co-Immunoprecipitation and Western Blot Analysis
Recombinant proteins or conditioned media were pre-cleared
with washed Protein G beads (Sigma) for 1 hour, spun down to
pellet the beads, and the supernatant was collected. Antibody was
added and incubated for 3 hours at 4uC with constant rotation.
Protein G beads that had been pre-cleared for 3 hours with 1 mg/
ml BSA and then washed 5 times with PBS, were added to the
protein-antibody mixture and incubated for 1 hour at 4uCo na
rotator. The beads were washed 5 times with lysis buffer, and the
protein was eluted by boiling for 5 minutes in 4X sample buffer.
The samples were run via SDS-PAGE on a blank gel, transferred
to a nitrocellulose membrane, and blocked with antibodies against
Hsp90a.
Zymography/MMP-2 Activation
Pro-MMP-2 was activated by incubating recombinant MMP-2
(0.4 mg) in 4-Aminophenylmercuric Acetate (APMA) (1 mM in
0.1 M Tris-HCl) for 2 hours at 37uC. For in vitro Hsp90a
activation of MMP-2, the indicated recombinant proteins and
ATP or ATPcS were incubated in activation buffer (25 mM Tris
pH 7.5, 50 mM KCl, 5 mM MgCl2, and 20 mM NaMoO4 [20])
for 30 minutes at 30uC. The samples were boiled for 5 minutes in
4X non-reducing sample buffer and run on a 10% polyacrylamide
gel containing gelatin (4 mg/ml) [21,22]. The gel was renatured in
2.5% Triton X-100 for 40 minutes at room temperature, washed
in digestion buffer (0.1 M Tris pH 7.5, 50 mM CaCl2 and 1%
NaN3) for 30 minutes and then incubated in fresh digestion buffer
at 37uC for 18 hours. For activation of MMP-2 in conditioned
media, conditioned media and untreated media were collected and
concentrated. Aliquots of PBS, untreated media, and conditioned
media (30 ml) were treated with the indicated inhibitors and then
pro-MMP-2 (0.75 mg) was added. Samples were incubated with
gentle agitation at room temperature for 5 minutes, boiled for
5 minutes in 4X reducing sample buffer and run on an SDS-
PAGE gel, transferred to a nitrocellulose membrane, and blocked
with antibodies against MMP-2. Densitometry was performed to
determine the relative amount of active MMP-2 in both the
zymograms and SDS-PAGE gels.
FITC-Casein Assay
A FITC-Casein Assay (Sigma, MO) was performed according to
the manufacturer’s directions except for the substitution of the
incubation buffer for buffer (A): 50 mM Tris–HCl, pH 7.5, 0.1 M
NaCl, 10 mM CaCl2, and 0.1% Brij-35 [23]. In brief, pro-MMP-2
was activated with APMA for 2 hours as described above. Pro-
MMP-2 was combined with the indicated recombinant proteins in
activation buffer for 30 minutes at 30uC. The samples were then
added to the indicated amount of buffer (A) and FITC-Casein
substrate and allowed to incubate at 37uC in the dark for 1 hour.
The reaction was then stopped with 150 ul of 0.6 N Trichlor-
oacetic acid (TCA). The samples were centrifuged on a table top
centrifuge for 10 minutes at 10,000 g. 2 ul of the supernatant was
added to 200 ul of assay buffer in each well of black 96-well plate
and read on a plate reader (excitation wavelength of 485 nm and
an emission wavelength of 535 nm).
Invasion Assay
2.5 million MDA-MB-231 or SUM1315 cells were plated on
five T-75 flasks and incubated for 48 hours. Then 2610
4 MDA-
MB-231 or SUM1315 cells were labeled with cell tracker orange
(CMTMR, Invitrogen), treated with either 10 mg/ml 17AAG,
30 mM Vehicle (water), or 30 mM Methylene Blue, and added to
each well of a porous membrane (pore size 8 mm (Neuroprobe,
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Matrigel (BD Biosciences, Bedford, MA)). The cells were
incubated for 24 hours at 37uC under 7.5% CO2. The number
of cells that had invaded into the matrigel and migrated through
the pores of the membrane was quantified for each well with a
fluorescence plate reader (excitation 544 nm, emission 590 nm).
Depletion of Hsp90a and Hsp70 from conditioned media
Conditioned media was collected as described above and pre-
cleared with Protein G beads for 1 hour. Antibodies against
Hsp90a or Hsp70 were added to the pre-cleared conditioned
media and incubated for 3 hours. Afterwards, Protein G beads
were added to the conditioned media-antibody mixture and
rotated at 4uC overnight. The beads were then spun down and the
depleted supernatant was collected.
Wound Healing
MDA-MB-231-s4175 cells were plated (1.5610
5/per chamber)
in an 8-well chamber slide. The cells were incubated for 18 hours
to allow formation of a monolayer. A wound was created in the
monolayer with a 200 ml pipette tip. Cells were washed once with
DMEM to remove any detached cells and pictures were taken of
the wounds (0 hour time point). Serum-free DMEM, untreated
conditioned medium obtained from MDA-231-s4175 cells,
Hsp90a-depleted, Hsp70-depleted, or fibronectin-depleted (serves
as a depletion control) conditioned media, or inhibitor-treated
conditioned media was added to the wounded cells. The cells were
incubated at 37uC under 7.5% CO2. Images were taken to
determine the amount of cell movement from the wound edge at
16 hours (16 hour time point). Wound closure was quantified by
measuring the area of the wound before and after the 16-hour
incubation period.
Cell Viability Assay
Plated 20,000 MDA-MB-231 cells per well in a 96-well plate for
24 hours before addition of increasing volumes of 17-AAG, SPS-
771, or Rabbit IgG that was incubated for 24 hours. Cells were
subjected to a Celltiter 96 Aqueous Non-radioactive Cell
Proliferation Assay (Promega, WI). The number of viable cells
was calculated as previously described [24].
Results
Hsp90a, MMP-2, and the co-chaperones Hsp70, Hop,
Hsp40, and p23 are present in breast cancer cell
conditioned media
Intracellular Hsp90a forms an activation complex with various
co-chaperones including Hsp70, Hop, Hsp40, p23, and Hip [25].
This complex carries out the conformational changes necessary to
fold or activate the client protein. We proposed that extracellular
Hsp90a is functioning in a similar manner to intracellular Hsp90a;
therefore we tested for the presence of the above co-chaperones in
breast cancer cell conditioned media. We probed the extracellular
media of the invasive breast cancer cell line, MDA-MB-231, for
these co-chaperones. We observed Hsp70, Hop, Hsp40, and p23,
but not Hip, in the conditioned media (Fig. 1). In addition to not
finding Hip, the intracellular protein b-tubulin was not detected
(Fig. 1), which indicates that the co-chaperones in the media were
not the result of intracellular leakage from lysed or dying cells. All
the co-chaperones were less abundant in conditioned media than
in cell lysate. Hsp90a, Hsp70, and Hop were three times more
abundant in the lysate than in the conditioned media, while
MMP-2, Hsp40, and p23 were, respectively, 8, 6, and 10 times
more abundant in the lysate than the conditioned media as
determined by densitometry. These results, which demonstrate the
presence of co-chaperones outside of invasive cancer cells, confirm
and extend our previously published data that co-chaperones are
present in conditioned media of fibrosarcoma cells [26], suggesting
a general role for extracellular co-chaperones in cancer progres-
sion.
Hsp90a interacts with Hsp70, Hop, Hsp40, p23, and
MMP-2 both in vitro and in conditioned media
To determine whether these extracellular co-chaperones can
interact with Hsp90a, in vitro interaction was tested by co-
immunoprecipitation with recombinant proteins and antibodies
against Hsp70, Hop, Hsp40, p23, and MMP-2. Hsp90a was found
to co-immunoprecipitate with each of these recombinant proteins
(Fig. 2a). To determine if extracellular co-chaperones interact with
Hsp90a in culture, interaction was tested in conditioned media from
MDA-MB-231 breast cancer cells. Confirming our previous
findings [13] and our in vitro results, Hsp90a interacted with
MMP-2 in MDA-MB-231 conditioned media. Hsp90a also
interacted with Hsp70, Hop, Hsp40, and p23 (Fig. 2b). To further
ensure that the observed interaction was specific, co-immunopre-
cipitation with Hsp90a was tested for fibronectin, a protein
detected outside of MDA-MB-231 cells that is not known to
interact with Hsp90a. As can be seen in Fig. 2c, fibronectin did
not co-immunoprecipitate with Hsp90a. Together, these findings
show that Hsp90a forms a complex with Hsp70, Hop, Hsp40, and
p23, in addition to MMP-2, both in vitro and in breast cancer cell
media [5,8].
Hsp70, Hop, Hsp40, and p23 increase the interaction
between Hsp90a and MMP-2, enhancing MMP-2
activation
Intracellular Hsp90a relies on co-chaperones to recruit its client
proteins and to assist in the formation of an activation complex
[27]. Consequently, the interaction between Hsp90a and its client
proteins increases in the presence of these co-chaperones [5]. To
Figure 1. Hsp90a, MMP-2 and several co-chaperones are
present in the conditioned media of breast cancer cells. Lysate
and conditioned media were collected from MDA-MB-231 cells. 20 mg
of protein was loaded into each lysate lane and 80 mg of protein was
loaded into each conditioned media lane and immunoblotted for the
Hsp90a, MMP-2, Hsp70, Hop, Hsp40, p23, Hip, and b-tubulin. The first
six proteins were found to be present in both the cell lysate and in the
conditioned media, while Hip was only found in the lysate. b-tubulin
was used as a negative control. The molecular weight markers are
indicated on the left.
doi:10.1371/journal.pone.0018848.g001
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the interaction between Hsp90a and MMP-2, we performed co-
immunoprecipitations with Hsp90a and MMP-2 either alone or in
the presence of the four co-chaperones that we previously
determined were outside of the cell. Figure 3 shows that addition
of the co-chaperones increased the interaction between Hsp90a
and MMP-2 by 2.9 fold (Fig. 3, p,0.01). We observed a small
amount of non-specific binding, which was accounted for in the
densitometry calculations.
Previous studies on Hsp90a and MMP-2 activation were
preformed with conditioned media, which contains many proteins
including active MMP-2. It was not known if Hsp90a alone could
activate MMP-2 in vitro. In the following experiments, MMP-2
activity was assessed by measuring the relative amount of digestion
seen in a gelatin zymogram. When MMP-2 is activated in an in
vitro environment three bands are observed: the 72 kDa band is
pro-MMP-2; the 64 kDa band is an intermediate, active form that
is generated during in vitro activation; and the 62 kDa band
represents the normal sized active MMP-2. Activation of MMP-2
in a completely in vitro environment, such as the above experiment,
results in an active, 64 kDa, isoform, as can be seen in Fig. 4a
[18,28,29]. We then investigated if pro-MMP-2 can be activated
by Hsp90a, Hsp70, Hop, Hsp40, and p23 in vitro. When these
proteins were added to pro-MMP-2, no activation was observed
(Fig. 4). However, when we combined this mixture with a very
small amount of activated MMP-2 (4 pg), cleavage and activation
of pro-MMP-2 occurred. We observed a significant increase in the
generation of the 64 kDa band (33% p,0.05) when Hsp90a and
the co-chaperones were present, compared with MMP-2 alone
(Fig. 4a, Figure S1a). To show that Hsp90a and the individual co-
chaperones are important in this activation, we removed Hsp90a,
Hsp70, or Hsp40 from the complex and in each instance saw a
significant decrease in the amount of activated MMP-2 (Figure
S1b). We also used a FITC-Casein assay to quantitatively measure
the activation of MMP-2. We found the level of activation to be
very similar (38%) to that detected in the zymogram (Figure S1c).
These findings demonstrate that the added co-chaperones can
assist in MMP-2 activation in vitro and suggests a role for the
complex in facilitating active MMP-2 cleavage of pro-MMP-2.
The amount of activation observed is modest (33%), perhaps
because there are additional components in the extracellular
media that further increase the efficiency of the MMP-2 activation
in vivo. For example, while we observed in vitro activation of MMP-
2 in the absence of ATP, ATP could potentially increase the rate
of MMP-2 activation as it does for the intracellular client proteins
of Hsp90a. Therefore, we tested if ATP could enhance activation
by combining the Hsp90a-co-chaperone complex proteins as
described above, with 100 mM ATP, 100 mM ATPcS or no ATP
and measuring the amount of MMP-2 activity. We found that
neither ATP nor ATPcS increased MMP-2 activity and that
ATPcS decreased MMP-2 activity (Fig. 4b). These results indicate
that ATP does not enhance Hsp90a-mediated MMP-2 activation.
This supports our hypothesis that extracellular Hsp90a functions
with co-chaperones to assist in the activation of MMP-2 and can
do so independently of ATP.
Inhibiting Hsp70 reduces MMP-2 activation
We next investigated whether the endogenous Hsp90a and co-
chaperones present in the extracellular media of breast cancer cells
can activate MMP-2. First, we demonstrated that the conditioned
media collected from MDA-MB-231 cells contain the necessary
components to activate MMP-2. In brief, recombinant pro-MMP-
Figure 2. Hsp90a, MMP-2, Hsp70, Hop, Hsp40, and p23 interact in vitro and outside of the cell. (a) 1 mg Hsp90a, 0.5 mg MMP-2, 1 mg
Hsp70, 0.25 mg Hop, 0.1 mg Hsp40, and 0.25 mg p23 recombinant proteins were combined and the indicated IP antibody was added to the proteins.
The protein complexes were pulled down using Protein G beads. The immunoprecipitate was then run on an SDS-PAGE and blotted for Hsp90a.( b
and c) Conditioned media was collected from MDA-MB-231 cells and the indicated IP antibody was added to equal volumes of conditioned media.
The resulting complex was then pulled down with Protein G beads and run on an SDS-PAGE and blotted for Hsp90a.
doi:10.1371/journal.pone.0018848.g002
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conditioned media. Then the amount of active MMP-2 was
measured by SDS-PAGE and western blotted for MMP-2.
Western blotting is a more accurate way of assessing the amount
of active MMP-2 than zymography when comparing levels of
active MMP-2 from samples which may contain TIMPs, which
can interfere with MMP-2 activity [30]. When cellular compo-
nents are present, as in the conditioned media experiments in
Fig. 5a, MMP-2 is processed to the fully active 62 kDa band and
the middle 64 kDa band is usually not seen [31]. As shown in
Fig. 5a, the MMP-2 added to the conditioned media has 3.5-fold
(P,0.01) greater activity than MMP-2 added to PBS and 2.5-fold
(P,0.05) greater activity than MMP-2 added to untreated media.
The amount of active MMP-2 is much greater than the amount of
MMP-2 present in the conditioned media (conditioned media
alone, lane 1), so the increase in MMP-2 activity is not the result of
endogenous MMP-2. The amount of MMP-2 in the control lane is
significantly less than that shown in figure one due to a lower
exposure time for the film and the use of less conditioned media in
the blot.
We then tested if Hsp70, a component of the co-chaperone
complex, contributed to the observed MMP-2 activation by using
an Hsp70 inhibitor, Methylene Blue [32]. When conditioned
media was subject to Methylene Blue treatment, MMP-2
activation was reduced by 53% (p,0.01) (Fig. 5b). These findings
show that Methylene Blue can reduce MMP-2 activation in the
conditioned media, suggesting a role for Hsp70 in MMP-2
activation in breast cancer cells. It is possible that other proteases
could influence MMP-2 activation, but the significant decrease in
MMP-2 activation when Hsp70 was inhibited suggests that the
Hsp90a-activation complex plays an important role in this
activation.
Extracellular Hsp90a and Hsp70 increase breast cancer
cell migration
We next investigated the ability of the Hsp90a activation
complex, specifically Hsp70, to increase breast cancer cell
migration using a wound healing assay. MMPs are central in
cancer cell invasion due to their ability to digest components of the
extracellular matrix, allowing cancer cells to intravasate into the
bloodstream [33]. MMPs have also been implicated in cancer cell
migration. For instance, MMP-2 can cleave the adhesive contacts
and cellular networks that cells use to adhere to their basement
membrane, facilitating cell migration [14,34,35]. Therefore, we
hypothesized that extracellular Hsp90a and Hsp70 increase
cancer cell migration. To test this, we performed wound healing
assays with MDA-231-s4175 cells, a derivative of the MDA-MB-
231 cell line. MDA-MB-231 cells move slowly in in vitro wound
healing assays and are thus not suited for this assay, whereas the
s4175 derivative of the MDA-MB-231 cell line is highly motile in
this assay. The MDA-MB-231 s4175 cell line was selected for its
ability to metastasize to the lungs in a mouse model by Massague ´
et al. [36] Prior to the wound healing assays we verified that all of
the co-chaperones identified in the original MDA-MB-231 line
were also present in this sub-line (Figure S2). MMP-2 and all the
co-chaperones examined are found at higher levels in the
Figure 3. The presence of Hsp70, Hop, Hsp40, and p23 increase the interaction between Hsp90a and MMP-2. Using recombinant
proteins, two co-immunoprecipitations were performed, one with Hsp90a and MMP-2 alone and one with Hsp90a, MMP-2, Hsp70, Hop, Hsp40, and
p23 present using the same quantities as in Fig. 2. Hsp90a and MMP-2 primary antibody were used to pull down Hsp90a and then the resulting
proteins were run on an SDS-PAGE and blotted for Hsp90a. The bands were then subject to densitometry to determine the relative interaction
between Hsp90a and MMP-2 with and without the presence of the co-chaperones. Experiments were repeated three times. P-value,0.001.
doi:10.1371/journal.pone.0018848.g003
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PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e18848Figure 4. Hsp90a and co-chaperones Hsp70, Hop, Hsp40, and p23 are sufficient to activate MMP-2 in vitro. (a) 0.5 mg Pro-MMP-2 was
incubated with and without 4 pg of activated MMP-2 and was incubated with 1 mg Hsp90a,1mg Hsp70, 0.25 mg Hop, 0.1 mg Hsp40, and 0.25 mg p23
recombinant proteins as indicated in the figure at 30uC for 30 minutes. 0.5 ug Pro-MMP-2 was activated in 1 mM APMA at 37uC for 2 hours (b) The
same amounts of protein as above were incubated with 100 mM ATP, 100 mM ATPcS, or alone at 30uC for 30 minutes. The proteins were then added
to a non-reducing sample buffer and then run on a gelatin containing SDS-PAGE. The gels were renatured for 40 minutes, digested for 18 hours and
stained with Coomassie Brilliant Blue. Hsp90a Chaperone Complex=Hsp90a, MMP-2, Hsp70, Hop, Hsp40, and p23. Experiments were repeated three
times. (a) P-value,0.05 (b) #P-value.0.3, *P-value,0.05.
doi:10.1371/journal.pone.0018848.g004
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PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e18848Figure 5. Conditioned media from cancer cells contains necessary components to activate MMP-2. (a) Conditioned media was collected
from MDA-MB-231 cells, samples were incubated with and without 0.75 mg pro-MMP-2 for 5 minutes and the relative amount of active MMP-2 was
analyzed via SDS-PAGE. (b) Conditioned media was collected and then treated with 30 mM Methylene Blue. 0.75 mg recombinant pro-MMP-2 was
added to treated and untreated conditioned media. Samples were incubated at room temperature for 5 minutes and the relative amount of active
MMP-2 was analyzed via SDS-PAGE. The difference in overall band intensity was taken into account in the densitometry calculations. Experiments
were repeated three times. (* P-value,0.01, #P-value,0.05).
doi:10.1371/journal.pone.0018848.g005
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parent line, consistent with the high invasiveness of these cells.
Wounds were created in monolayers of MDA-231-s4175 cells and
incubated with either untreated media or conditioned media
collected from other MDA-231-s4175 cells. Wound healing was
measured after 16 hours. Cells that had been fed conditioned
media migrated 16% (p,0.01) further than control cells that were
fed with normal media (Fig. 6a and b). Therefore additional
extracellular proteins present in conditioned media significantly
increased the rate of cell migration. When we immunodepleted
either Hsp90a or Hsp70 (Fig. 6c) the observed increase in
migration from the conditioned media disappeared; the wound
size did not significantly differ from the wound size of the control
media-treated cells. Roles for Hsp90a and Hsp70 in conditioned
media are further supported using inhibitors of these chaperones.
When 17AAG or Methylene Blue [32] was added to the
conditioned media there was a similar reduction in wound
healing. To verify that the reduction in migration is due to the
effect of Hsp90a on MMP-2 activation, and not Hsp90a affecting
some other factor, we compared undepleted conditioned media
treated with 40 nM Batimastat (a pan-MMP inhibitor) with
Hsp90a-depleted conditioned media treated with 40 nM Batima-
stat to wounded cells. There was no significant difference in the
reduction in migration between the two conditions, indicating that
the effect of Hsp90a depletion and MMP inhibition is not additive
(Fig. 6). A proliferation assay was performed to verify that the
above conditions did not alter the cells’ rate of proliferation (data
not shown).
Inhibiting Hsp70 reduces breast cancer cell invasion
Tumor cell invasion through the basement membrane and
extracellular matrix that surrounds cancer cells is a key step in
cancer cell metastasis and requires several cellular processes
including migration and extracellular matrix remodeling [3,37].
As Hsp70 increases Hsp90a-mediated MMP-2 activation and cell
migration, we hypothesized that inhibition of Hsp70 would reduce
cell invasion. Cells treated with 30 ug/ml of Methylene Blue saw a
50% decrease in invasion (p,0.05). Cells treated with vehicle
showed no decrease in invasion (Fig. 7). Methylene Blue is cell-
permeable, and can therefore also affect intracellular Hsp70.
When cells in our invasion assay were treated with 40 nM
Batimastat, we observed a similar decrease in invasion as seen with
the Hsp70 or Hsp90a inhibitors. Combining Batimastat with the
Hsp70 or Hsp90a inhibitors, we saw additive effects on invasion.
These findings suggest that while Hsp70 and Hsp90a affect
migration primarily via MMP-2 activation, they may have other
roles in invasion. This is consistent with recent literature
demonstrating that other proteins required for invasiveness are
activated by Hsp70 and Hsp90a [7,12]. The difference between
migration and invasion is not surprising as invasion requires
additional cellular processes than migration. Taken together, these
findings indicate that Hsp90a and Hsp70 assist in MMP-2
activation, which increases breast cancer cell migration and
contributes to breast cancer invasion.
Discussion
Extracellular Hsp90a has been implicated in activating a
number of proteins important for disease- relevant processes
[38]. While the mechanism of Hsp90a activation of intracellular
client proteins is well understood, this is not yet known for
extracellular Hsp90a. Here we showed that extracellular Hsp90a
binds to these co-chaperones both in vitro and in the conditioned
media of MDA-MB-231 breast cancer cells. Moreover, the
presence of these co-chaperones increases MMP-2 binding to
Hsp90a and assists in MMP-2 activation in vitro and in conditioned
media. Depletion or inhibition of Hsp70 significantly decreases
MMP-2 activation, migration and invasion. Together, these
findings implicate Hsp70 as part of a co-chaperone complex that
acts with Hsp90a in MMP-2 activation and contributes to breast
cancer migration and invasion.
Recently, Song et al. (2010) showed that extracellular Hsp90a
can stabilize MMP-2, a process important for angiogenesis [39].
We did not observe the same MMP-2 degradation products as
Song et al. indicating the identification of a different mechanism
than the one described by their group (Figure S3). The different
cell types and processes addressed in the two studies suggest that
there may be multiple mechanisms for MMP-2 activation that
may depend on what other proteins are present extracellularly. In
this paper we show that extracellular Hsp90a, in conjunction with
co-chaperones including Hsp70, assists in MMP-2 activation in an
ATP-independent manner. It is well established that intracellular
Hsp90a works together with co-chaperones to activate its client
proteins, and we provide evidence suggesting that extracellular
Hsp90a functions in a similar way. Intracellular Hsp90a has a
minimum number of co-chaperones required for the activation of
its client proteins in vitro: Hsp70, Hop, Hsp40, and p23 [5,8]. Here,
we demonstrated that these co-chaperones are present outside of
MDA-MB-231 breast cancer cells.
Our findings suggest a role for Hsp70 in MMP-2 activation, as
well as in the migration and invasion of breast cancer cells. While
Methylene Blue is cell permeable and, can thus also inhibit
intracellular Hsp70, antibody-based immunodepletion experi-
ments implicate extracellular Hsp70 in these cancer-relevant
processes. While extracellular Hsp70 has been identified outside
immune cells, where it activates both the innate and adaptive
immune system by interacting with antigen-presenting cells [40],
its role in cancer cells and invasion is not yet clear [41]. Thus, our
findings implicate a second chaperone, Hsp70, in MMP-2
activation and breast cancer cell migration and invasion. In
addition, several of the other co-chaperones that we identified
outside of MDA-MB-231 cells were shown to be in HT-1080
fibrosarcoma cell media [26]. Similar to our results, this study also
did not find Hip in HT-1080 conditioned media; however they
also did not find Hsp70. The absence of Hip likely does not
impinge on the proposed mechanism because it is not required for
the activation of most Hsp90a client proteins [8]. We tested for
Hsp70 in HT-1080 conditioned media and did observe its
presence (data not shown). The difference between these results
is likely due to the use of better antibodies in the current study
(Cell Cycle. 2010 Dec 1;9(23):4769).
Our studies have focused on MMP-2 in breast cancer cells, but
extracellular Hsp90a may be important for other cancers as well
[12]. Many proteases that are secreted in their inactive form are
likely required for invasion and Hsp90a may also activate these
proteases. Recently, we identified plasmin as a second client
protein for extracellular Hsp90a in breast cancer and glioblastoma
conditioned media. Extracellular Hsp90a activates plasmin in
conjunction with tissue plasminogen activator and annexin II [12].
Hsp90a has been shown to be important in other cancers as well.
Extracellular Hsp90a is upregulated in malignant melanomas
[42], colorectal cancer [43] and fibrosarcomas [13], and is shown
to increase heregulin-induced Her-2 activation and signaling [7].
Outside of the cell, Hsp90a has been shown to have a role in
eliciting a host immune response against various antigens [44,45],
to activate plasminogen in smooth muscle cells during oxidative
stress [46], and increase wound healing in human dermal
fibroblasts [47]. Extracellular Hsp90a is also found in neurons
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PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e18848Figure 6. Hsp90a and its co-chaperone complex assist in wound healing. MDA-MB-231-s4175 cells were plated in an 8-well chamber slide
and allowed to grow to confluency. A wound was created in the monolayer and either media, untreated conditioned media, Hsp90a depleted
conditioned media, Hsp70 depleted conditioned media, 40 nM Batimastat (an MMP inhibitor) treated conditioned media, or 30 mM Methylene Blue
(an Hsp70 inhibitor) treated conditioned media were added to the cells. The cells were incubated for 16 hours, and then wound closure was
observed. (a) Representative pictures of wounded cells at 0 hours and 16 hours. (b) Graph of relative movement of cells. (c) SDS-PAGE showing
Hsp90a and Hsp70 depletion. Experiment was repeated three times. (*P-value,0.01).
doi:10.1371/journal.pone.0018848.g006
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stimulated keratinocytes [49]. While the mechanism of extracel-
lular Hsp90a in these additional roles is not known, we speculate
that the role we identified for Hsp90a and Hsp70 in MMP-2
activation may have bearing on the role of Hsp90a in these other
processes.
Interestingly, we did not find ATP to be necessary for MMP-2
activation, even though it is known to increase the reaction
efficiency for intracellular Hsp90a function. This may be due to the
fact that all of the conformational changes Hsp90a undergoes in its
chaperoning processes can be accessed without the presence of
ATP. Furthermore, recent work indicates that ATP is not necessary
for Hsp90a to carry out its chaperoning function [50]. In addition
we demonstrated that ATPcS decreased MMP-2 activity. This may
occur because when ATP is bound by Hsp90a it must be
hydrolyzed in order to evoke a conformation change to release its
client protein. Binding a slowly hydrolysable form of ATP would
reduce this transition and hence reduce the amount of MMP-2
activation. ATP has been found to be present outside of the cell in
sub-micromolar concentrations as an extracellular ATP gradient
[51,52]; however, these low concentrations are unlikely to affect the
function of extracellular Hsp90a. Our results are consistent with a
recent finding that the extracellular Hsp90a stabilization of MMP-2
is ATP-independent [39]. In addition, Hsp70, which we demon-
strated to be an essential co-chaperone in the Hsp90a-mediated
activation of MMP-2, is also known to be an ATPase. But as noted
above, we were able to obtain MMP-2 activation without the
assistance of ATP. There is little literature on the mechanism of
Hsp70outsideofthecellandwhetheritfunctionswiththeassistance
of ATP. Hsp70 has a high affinity for ADP and therefore needs a
highconcentrationofATP toinitiate the ATPasecyclewhichwould
be difficult to obtain outside of the cell. In addition, Hsp70 has been
found to have a high level of conformational plasticity, especially in
the nucleotide binding domain, possibly assisting in an ATP-
independent extracellular function [53]. Ourresults,combined with
other findings regarding Hsp70 function, suggest the existence of an
ATP-free mechanism for extracellular Hsp70. We previously
demonstrated that Hsp90a is exported via exosomes, but it is not
known how the other co-chaperones are exported [12]. Hsp70 has
been shown to be exported via exosomes in immune cells so it is
possible that Hsp70 and the other co-chaperones are exported in a
similar manner in breast cancer cells.
In this paper we identified an Hsp90a-co-chaperone complex
that is necessary to activate MMP-2 in vitro and in cell culture. We
identified the minimum components needed to obtain activation,
but it is likely that there are other proteins that make the activation
process more efficient. Since Hsp90a has been shown to activate
other extracellular proteins [12,47], it would be interesting to
determine if this activation complex exists in normal cells as well as
cancer cells and if it assists in the activation of other extracellular
client proteins. Hsp90a and Hsp70 may be found to chaperone or
activate other proteins using a similar mechanism to the activation
for MMP-2. As such, these extracellular proteins may be targets
for discovering drugs to prevent breast cancer invasion and
metastasis.
Supporting Information
Figure S1 (a and b) 0.5 mg Pro-MMP-2 and 4 pg of activated
MMP-2 were incubated with 1 mg Hsp90a,1mg Hsp70, 0.25 mg
Hop, 0.1 mg Hsp40, and 0.25 mg p23 recombinant proteins as
indicated in the figure at 30uC for 0, 5, 15, and 30 minutes. The
proteins were then added to a non-reducing sample buffer and run
on a gelatin containing SDS-PAGE. The gels were renatured for
40 minutes, digested for 18 hours and stained with coomassie
blue. Hsp90a Chaperone Complex=Hsp90a, MMP-2, Hsp70,
Hop, Hsp40, and p23. (c) A FITC-Casein Assay was performed
according to the manufactures directions except that the
incubation buffer was substituted with 50 mM Tris–HCl,
pH 7.5, 0.1 M NaCl, 10 mM CaCl2, and 0.1% Brij-35. Results
were normalized to the control. *P-value,0.01.
(TIF)
Figure 7. Inhibiting Hsp70 reduces breast cancer cell invasion in vitro. We performed invasion assays on MDA-MB-231 breast cancer cells to
test the Hsp90a inhibiting compound 17AAG, the Hsp70 inhibiting compound Methylene Blue and the pan-MMP inhibitor Batimastat in a Chemotex
invasion assay. We treated cells with 10 mg/ml 17AAG, 30 mg/ml water (vehicle), 30 mg/ml Methylene Blue or 40 nM Batimastat as indicated in the
figure. Experiments were repeated three times. (*P,0.01,**P,0.05, #P.0.05).
doi:10.1371/journal.pone.0018848.g007
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PLoS ONE | www.plosone.org 10 April 2011 | Volume 6 | Issue 4 | e18848Figure S2 Lysate and conditioned media were collected from
MDA-MB-231(s4175) cells. 20 mg of protein was loaded into each
lysate lane and 80 mg of protein was loaded into each conditioned
media lane and immunoblotted for the Hsp90a, MMP-2, Hsp70,
Hop, Hsp40, and p23. The molecular weight markers are
indicated on the left.
(TIF)
Figure S3 PBS, Serum-free media, or conditioned media
collected from MDA-MB-231 cells were incubated with and
without 0.75 mg pro-MMP-2 for 5 minutes at room temperature
and the relative amount of active MMP-2 was analyzed via SDS-
PAGE.
(TIF)
Acknowledgments
We greatly appreciate the gift of MDA-MB-231-s4175 cells from Dr. Joan
Massague ´ (Memorial Sloan-Kettering Cancer Center, New York, New
York). We would like to give our thanks to Dr. Michael Forgac, Dr. Gary
Sahagian, and Dr. Charlotte Kuperwasser for their helpful discussion.
We would like to dedicate this manuscript in memory of Dr. J. Fred
‘‘Paulo’’ Dice, who made invaluable contributions to this project.
Author Contributions
Conceived and designed the experiments: JDS JM DGJ. Performed the
experiments: JDS. Analyzed the data: JDS JM DGJ. Contributed reagents/
materials/analysis tools: JDS DGJ. Wrote the paper: JDS DGJ.
References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009.
CA Cancer J Clin 59: 225–249.
2. Ernst MF, van de Poll-Franse LV, Roukema JA, Coebergh JW, van Gestel CM,
et al. (2007) Trends in the prognosis of patients with primary metastatic breast
cancer diagnosed between 1975 and 2002. Breast 16: 344–351.
3. Brooks SA, Lomax-Browne HJ, Carter TM, Kinch CE, Hall DM (2010)
Molecular interactions in cancer cell metastasis. Acta Histochem 112: 3–25.
4. Nguyen DX, Bos PD, Massague J (2009) Metastasis: from dissemination to
organ-specific colonization. Nat Rev Cancer 9: 274–284.
5. Grenert JP, Johnson BD, Toft DO (1999) The importance of ATP binding and
hydrolysis by hsp90 in formation and function of protein heterocomplexes. J Biol
Chem 274: 17525–17533.
6. Pratt WB, Toft DO (2003) Regulation of signaling protein function and
trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med
(Maywood) 228: 111–133.
7. Sidera K, Gaitanou M, Stellas D, Matsas R, Patsavoudi E (2008) A critical role
for HSP90 in cancer cell invasion involves interaction with the extracellular
domain of HER-2. J Biol Chem 283: 2031–2041.
8. Kanelakis KC, Murphy PJ, Galigniana MD, Morishima Y, Takayama S, et al.
(2000) hsp70 interacting protein Hip does not affect glucocorticoid receptor
folding by the hsp90-based chaperone machinery except to oppose the effect of
BAG-1. Biochemistry 39: 14314–14321.
9. Workman P (2004) Combinatorial attack on multistep oncogenesis by inhibiting
the Hsp90 molecular chaperone. Cancer Lett 206: 149–157.
10. Maloney A, Workman P (2002) HSP90 as a new therapeutic target for cancer
therapy: the story unfolds. Expert Opin Biol Ther 2: 3–24.
11. Neckers L, Ivy SP (2003) Heat shock protein 90. Curr Opin Oncol 15: 419–424.
12. McCready J, Sims JD, Chan D, Jay DG (2010) Secretion of extracellular
hsp90alpha via exosomes increases cancer cell motility: a role for plasminogen
activation. BMC Cancer 10: 294.
13. Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, et al. (2004)
Functional proteomic screens reveal an essential extracellular role for hsp90
alpha in cancer cell invasiveness. Nat Cell Biol 6: 507–514.
14. Jezierska A, Motyl T (2009) Matrix metalloproteinase-2 involvement in breast
cancer progression: a mini-review. Med Sci Monit 15: RA32–40.
15. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C (2004) Matrix
metalloproteinases in cancer: from new functions to improved inhibition
strategies. Int J Dev Biol 48: 411–424.
16. Ra HJ, Parks WC (2007) Control of matrix metalloproteinase catalytic activity.
Matrix Biol 26: 587–596.
17. Bartsch JE, Staren ED, Appert HE (2003) Matrix metalloproteinase expression
in breast cancer. J Surg Res 110: 383–392.
18. Nagase H (1997) Activation mechanisms of matrix metalloproteinases. Biol
Chem 378: 151–160.
19. Kosano H, Stensgard B, Charlesworth MC, McMahon N, Toft D (1998) The
assembly of progesterone receptor-hsp90 complexes using purified proteins.
J Biol Chem 273: 32973–32979.
20. Felts SJ, Owen BA, Nguyen P, Trepel J, Donner DB, et al. (2000) The hsp90-
related protein TRAP1 is a mitochondrial protein with distinct functional
properties. J Biol Chem 275: 3305–3312.
21. Chen JH, Lin HH, Chiang TA, Hsu JD, Ho HH, et al. (2008) Gaseous nitrogen
oxide promotes human lung cancer cell line A549 migration, invasion, and
metastasis via iNOS-mediated MMP-2 production. Toxicol Sci 106: 364–375.
22. Loftus JP, Belknap JK, Black SJ (2006) Matrix metalloproteinase-9 in laminae of
black walnut extract treated horses correlates with neutrophil abundance. Vet
Immunol Immunopathol 113: 267–276.
23. Quesada AR, Barbacid MM, Mira E, Fernandez-Resa P, Marquez G, et al.
(1997) Evaluation of fluorometric and zymographic methods as activity assays
for stromelysins and gelatinases. Clin Exp Metastasis 15: 26–32.
24. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, et al. (2003) A high-
affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
Nature 425: 407–410.
25. Buchner J (1999) Hsp90 & Co. - a holding for folding. Trends Biochem Sci 24:
136–141.
26. Eustace BK, Jay DG (2004) Extracellular roles for the molecular chaperone,
hsp90. Cell Cycle 3: 1098–1100.
27. Pratt WB, Toft DO (1997) Steroid receptor interactions with heat shock protein
and immunophilin chaperones. Endocr Rev 18: 306–360.
28. Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE (1990)
Multiple modes of activation of latent human fibroblast collagenase: evidence for
the role of a Cys73 active-site zinc complex in latency and a ‘‘cysteine switch’’
mechanism for activation. Proc Natl Acad Sci U S A 87: 364–368.
29. Strongin AY, Marmer BL, Grant GA, Goldberg GI (1993) Plasma membrane-
dependent activation of the 72-kDa type IV collagenase is prevented by complex
formation with TIMP-2. J Biol Chem 268: 14033–14039.
30. Ratnikov BI, Deryugina EI, Strongin AY (2002) Gelatin zymography and
substrate cleavage assays of matrix metalloproteinase-2 in breast carcinoma cells
overexpressing membrane type-1 matrix metalloproteinase. Lab Invest 82:
1583–1590.
31. Lafleur MA, Hollenberg MD, Atkinson SJ, Knauper V, Murphy G, et al. (2001)
Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is
membrane-type-MMP-dependent in human umbilical vein endothelial cells and
generates a distinct 63 kDa active species. Biochem J 357: 107–115.
32. Wang AM, Morishima Y, Clapp KM, Peng HM, Pratt WB, et al. (2010)
Inhibition of hsp70 by methylene blue affects signaling protein function and
ubiquitination and modulates polyglutamine protein degradation. J Biol Chem
285: 15714–15723.
33. Haas TL (2005) Endothelial cell regulation of matrix metalloproteinases.
Can J Physiol Pharmacol 83: 1–7.
34. Ray JM, Stetler-Stevenson WG (1995) Gelatinase A activity directly modulates
melanoma cell adhesion and spreading. Embo J 14: 908–917.
35. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ (1997) Matrix metalloprotei-
nase inhibitors. Invest New Drugs 15: 61–75.
36. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, et al. (2005) Genes that
mediate breast cancer metastasis to lung. Nature 436: 518–524.
37. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57–70.
38. Song X, Luo Y (2010) The regulatory mechanism of Hsp90alpha secretion from
endothelial cells and its role in angiogenesis during wound healing. Biochem
Biophys Res Commun.
39. Song X, Wang X, Zhuo W, Shi H, Feng D, et al. (2010) The regulatory
mechanism of extracellular Hsp90{alpha} on matrix metalloproteinase-2
(MMP-2) processing and tumor angiogenesis. J Biol Chem.
40. Multhoff G (2007) Heat shock protein 70 (Hsp70): membrane location, export
and immunological relevance. Methods 43: 229–237.
41. Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C (2007) Intracellular
and extracellular functions of heat shock proteins: repercussions in cancer
therapy. J Leukoc Biol 81: 15–27.
42. Becker B, Multhoff G, Farkas B, Wild PJ, Landthaler M, et al. (2004) Induction
of Hsp90 protein expression in malignant melanomas and melanoma metastases.
Exp Dermatol 13: 27–32.
43. Chen JS, Hsu YM, Chen CC, Chen LL, Lee CC, et al. (2010) Secreted heat
shock protein 90{alpha} induces colorectal cancer cell invasion through CD91/
LRP-1 and NF-{kappa}B-mediated integrin {alpha}V expression. J Biol Chem.
44. Tsutsumi S, Neckers L (2007) Extracellular heat shock protein 90: a role for a
molecular chaperone in cell motility and cancer metastasis. Cancer Sci 98:
1536–1539.
45. Tsutsumi S, Scroggins B, Koga F, Lee MJ, Trepel J, et al. (2008) A small
molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and
invasion. Oncogene 27: 2478–2487.
46. Chung SW, Lee JH, Choi KH, Park YC, Eo SK, et al. (2009) Extracellular heat
shock protein 90 induces interleukin-8 in vascular smooth muscle cells. Biochem
Biophys Res Commun 378: 444–449.
47. Li W, Li Y, Guan S, Fan J, Cheng CF, et al. (2007) Extracellular heat shock
protein-90alpha: linking hypoxia to skin cell motility and wound healing. Embo J
26: 1221–1233.
Hsp70 and Hsp90a Assist in MMP-2 Activation
PLoS ONE | www.plosone.org 11 April 2011 | Volume 6 | Issue 4 | e1884848. Sidera K, Samiotaki M, Yfanti E, Panayotou G, Patsavoudi E (2004)
Involvement of cell surface HSP90 in cell migration reveals a novel role in the
developing nervous system. J Biol Chem 279: 45379–45388.
49. Cheng CF, Fan J, Fedesco M, Guan S, Li Y, et al. (2008) Transforming growth
factor alpha (TGFalpha)-stimulated secretion of HSP90alpha: using the receptor
LRP-1/CD91 to promote human skin cell migration against a TGFbeta-rich
environment during wound healing. Mol Cell Biol 28: 3344–3358.
50. Mickler M, Hessling M, Ratzke C, Buchner J, Hugel T (2009) The large
conformational changes of Hsp90 are only weakly coupled to ATP hydrolysis.
Nat Struct Mol Biol 16: 281–286.
51. Deli T, Csernoch L (2008) Extracellular ATP and cancer: an overview with
special reference to P2 purinergic receptors. Pathol Oncol Res 14: 219–231.
52. Trautmann A (2009) Extracellular ATP in the immune system: more than just a
‘‘danger signal’’. Sci Signal 2: pe6.
53. Powers MV, Jones K, Barillari C, Westwood I, van Montfort RL, et al. (2010)
Targeting HSP70: The second potentially druggable heat shock protein and
molecular chaperone? Cell Cycle 9.
Hsp70 and Hsp90a Assist in MMP-2 Activation
PLoS ONE | www.plosone.org 12 April 2011 | Volume 6 | Issue 4 | e18848